Cancer therapy and vaccination

Journal of Immunological Methods

Volumn 382, Issue 1-2, 2012, Pages 1-23

  Aly, Hamdy A A ^a,b  

^a Al Azhar University   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Cancer; Gold nanoparticles; Survivin; Vaccine

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZACITIDINE; B7 ANTIGEN; CANCER VACCINE; CASPASE 9; CD28 ANTIGEN; CELL EXTRACT; CISPLATIN; DNA; DNA VACCINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GOLD NANOPARTICLE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 10; NANOCARRIER; PACLITAXEL; PROTEIN; RIBOZYME; SURVIVIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CARCINOGENESIS; CELL FUNCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; DRUG DELIVERY SYSTEM; EPIGENETICS; GENE MUTATION; HEPATITIS B; HEPATITIS C; HISTONE MODIFICATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; IMMUNOSURVEILLANCE; IONIZING RADIATION; LIVER CELL CARCINOMA; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; VIRUS RECOMBINANT;

ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NANOTECHNOLOGY; NEOPLASMS; VACCINATION;

EID: 84863581637     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2012.05.014     Document Type: Review

References (227)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75. 2-3.
2. Abbas A., Lichtman A., Pillai S. Cellular and Molecular Immunology 2007, Saunders, Elsevier, NewYork, Amsterdam. 6th ed.
3. Ackerman A.L., Cresswell P. Cellular mechanisms governing cross-presentation of exogenous antigens. Nat. Immunol. 2004, 5:678.
4. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499.
5. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783.
6. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., Walters P. Molecular Biology of the Cell 2002, Garland Science, New York and London. 4th ed.
7. Alferink J., Tafuri A., Vestweber D., Hallmann R., Hammerling G.J., Arnold B. Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 1998, 282:1338.
8. Allen P.D., Bustin S.A., Newland A.C. The role of apoptosis (programmed cell death) in haemopoiesis and the immune system. Blood Rev. 1993, 7:63.
9. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 2253:8581.
10. Altieri D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 81:61.
11. Antonia S.J., Mirza N., Fricke I., Chiappori A., Thompson P., Williams N., Bepler G., Simon G., Janssen W., Lee J.H., Menander K., Chada S., Gabrilovich D.I. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 2006, 12:878.
12. Aydin D., Feychting M., Schüz J., Tynes T., Andersen T.V., Schmidt L.S., Poulsen A.H., Johansen C., Prochazka M., Lannering B., Klæboe L., Eggen T., Jenni D., Grotzer M., Von der Weid N., Kuehni C.E., Röösli M. Mobile phone use and brain tumors in children and adolescents: a multicenter case-control study. J. Natl. Cancer Inst. 2011, 103:1264.
13. Baban D.F., Seymour L.W. Control of tumour vascular permeability. Adv. Drug Deliv. Rev. 1998, 34:109.
14. Banchereau J., Steinmar R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245.
15. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767.
16. Bartlett J.B., Dredge K., Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer 2004, 4:314.
17. Baselga J., Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J. Clin. Oncol. 2005, 23:2445.
18. Basu A., Haldar S. Signal-induced site specific phosphorylation targets Bcl2 to the proteasome pathway. Int. J. Oncol. 2002, 21:597.
19. Bawarski W.E., Chidlowsky E., Bharali D.J., Mousa S.A. Emerging nanopharmaceuticals. Nanomedicine 2008, 4:273.
20. Baxevanis C.N., Perez S.A., Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 2009, 25:317.
21. Bender C.M., Pao M.M., Jones P.A. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 1998, 58:95.
22. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 36:401.
23. Bernstein B.E., Meissner A., Lander E.S. The mammalian epigenome. Cell 2007, 128:669.
24. Bicaku E., Marchion D.C., Schmitt M.L., Munster P.N. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 2008, 68:1513.
25. Biroccio A., Leonetti C., Zupi G. The future of antisense therapy: combination with anticancer treatments. Oncogene 2003, 2242:6579.
26. Blanc-Brude O.P., Mesri M., Wall N.R., Plescia J., Dohi T., Altieri D.C. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin. Cancer Res. 2003, 97:2683.
27. Bocchia M., Bronte V., Colombo M.P., Vincentis A.D., Di Nicola M., Forni G., Lanata L., Lemoli R.M., Massaia M., Rondelli D., Zanon P., Tura S. Antitumor vaccination: where we stand. Haematologica 2000, 85:1172.
28. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 2004, 56:1649.
29. Brueckner B., Stresemann C., Kuner R., Mund C., Musch T., Meister M., Sultmann H., Lyko F. The human let-7a-3 locus contains an epigenetically regulated micro-RNA gene with oncogenic function. Cancer Res. 2007, 67:1419.
30. Buckley M.T., Yoon J., Yee H., Chiriboga L., Liebes L., Ara G., Qian X., Bajorin D.F., Sun T.T., Wu X.R., Osman I. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J. Transl. Med. 2007, 5:49.
31. Bueno M.J., Perez de Castro I., Gomez de Cedron M., Santos J., Calin G.A., Cigudosa J.C., Croce C.M., Fernandez-Piqueras J., Malumbres M. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008, 13:496.
32. Cardis E., Armstrong B.K., Bowman J.D., Giles G.G., Hours M., Krewski D., McBride M., Parent M.E., Sadetzki S., Woodward A., Brown J., Chetrit A., Figuerola J., Hoffmann C., Jarus-Hakak A., Montestruq L., Nadon L., Richardson L., Villegas R., Vrijheid M. Risk of brain tumours in relation to estimated RF dose from mobile phones: results from five Interphone countries. Occup. Environ. Med. 2011, 68:631.
33. Chaitanya G.V., Eeka P., Munker R., Alexander J.S., Babu P.P. Role of cytotoxic protease granzyme-b in neuronal degeneration during human stroke. Brain Pathol. 2011, 21:16.
34. Chen D., Dou Q.P. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 2010, 11:459.
35. Chen X., Chang C.H., Goldenberg D.M. Novel strategies for improved cancer vaccines. Expert Rev. Vaccines 2009, 8:567.
36. Cheng J.C., Yoo C.B., Weisenberger D.J., Chuang J., Wozniak C., Liang G., Marquez V.E., Greer S., Orntoft T.F., Thykjaer T., Jones P.A. Preferential response of cancer cells to zebularine. Cancer Cell 2004, 6:151.
37. Chun J.Y., Hu Y., Pinder E., Wu J., Li F., Gao A.C. Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter. Mol. Cancer Ther. 2007, 69:2572.
38. Chung Y.L., Wang A.J., Yao L.F. Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: implications for increasing therapeutic gain in cancer radiotherapy. Mol. Cancer Ther. 2004, 3:317.
39. Coley W.B. End results in Hodgkin's disease and lymphosarcoma treated by the mixed toxins of Erysipelas and Bacillus prodigiosus, alone or combined with radiation. Ann. Surg. 1928, 88:641.
40. Connor E.E., Mwamuka J., Gole A., Murphy C.J., Wyatt M.D. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005, 1:325.
41. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942.
42. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 2003, 370:737.
43. Dean E.J., Ranson M., Blackhall F., Holt S.V., Dive C. Novel therapeutic targets in lung cancer: inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat. Rev. 2007, 332:203.
44. den Haan J.M., Kraal G., Bevan M.J. Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J. Immunol. 2007, 178:5429.
45. Di Maro S., Pong R.C., Hsieh J.T., Ahn J.M. Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents. J. Med. Chem. 2008, 51:6639.
46. Disis M.L., Bernhard H., Jaffee E.M. Use of tumour-responsive T cells as cancer treatment. Lancet 2009, 373:673.
47. Dohi T., Beltrami E., Wall N.R., Plescia J., Altieri D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 2004, 1148:1117.
48. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4:11.
49. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:3539.
50. Dredge K., Marriott J.B., Todryk S.M., Dalgleish A.G. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol. Immunother. 2002, 51:521.
51. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 1021:33.
52. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 2491:49.
53. Ecke I., Petry F., Rosenberger A., Tauber S., Monkemeyer S., Hess I., Dullin C., Kimmina S., Pirngruber J., Johnsen S.A., Uhmann A., Nitzki F., Wojnowski L., Schulz-Schaeffer W., Witt O., Hahn H. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009, 69:887.
54. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457.
55. Elpek K.G., Yolcu E.S., Franke D.D., Lacelle C., Schabowsky R.H., Shirwan H. Ex vivo expansion of CD4+ CD25 + FoxP3 + T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J. Immunol. 2007, 179:7295.
56. English D.R., Armstrong B.K., Kricker A., Fleming C. Sunlight and cancer. Cancer Causes Control 1997, 8:271.
57. Ercolini A.M., Ladle B.H., Manning E.A., et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J. Exp. Med. 2005, 201(10):1591.
58. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu. Rev. Pharmacol. Toxicol. 2005, 45:629.
59. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 2008, 358:1148.
60. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143.
61. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759.
62. Feinberg A.P., Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89.
63. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., Schoch R., Gattermann N., Sanz G., List A., Gore S.D., Seymour J.F., Bennett J.M., Byrd J., Backstrom J., Zimmerman L., McKenzie D., Beach C., Silverman L.R. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10:223.
64. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893.
65. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 511:876.
66. Feychting M., Ahlbom A., Kheifets L. EMF and health. Annu. Rev. Public Health 2005, 26:165.
67. Finn O.J. Cancer immunology. N. Engl. J. Med. 2008, 358:2704.
68. Fraga M.F., Herranz M., Espada J., Ballestar E., Paz M.F., Ropero S., Erkek E., Bozdogan O., Peinado H., Niveleau A., Mao J.H., Balmain A., Cano A., Esteller M. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res. 2004, 64:5527.
69. Frei P., Poulsen A.H., Johansen C., Olsen J.H., Steding-Jessen M., Schüz J. Use of mobile phones and risk of brain tumours: update of Danish cohort study. BMJ 2011, 343:1.
70. Fritz-Niggi H. Radiation Risk/Radiation Protection 1991, Hans Huber, Bern. 3rd ed.
71. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Immunology 1993, 90:11478.
72. Gallimore A., Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002, 107:5.
73. Gaudernack G. Prospects for vaccine therapy for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 2006, 20:229.
74. Ghosh P., Han G., De M., Kim C.K., Rotello V.M. Gold nanoparticles in delivery applications. Adv. Drug Deliv. Rev. 2008, 60:1307.
75. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:3235.
76. Govan V.A. A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Ther. Clin. Risk Manag. 2008, 4:65.
77. Gregory P.D., Wagner K., Horz W. Histone acetylation and chromatin remodeling. Exp. Cell Res. 2001, 265:195.
78. Grünewald J., Tsao M.L., Perera R., et al. Immunochemical termination of self-tolerance. Proc. Natl. Acad. Sci. 2008, 10:11276.
79. Gückel B., Stumm S., Rentzsch C., Marmé A., Mannhardt G., Wallwiener D. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A 02-matched situations in vitro as well as in vivo. Cancer Immunol. Immunother. 2005, 54:129.
80. Guillemard V., Saragovi H.U. Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets 2004, 4:313.
81. Gulley J.L., Madan R.A., Arlen P.M. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007, 25:B89.
82. Gunnarsson L.G. Mobile phones and brain tumours - a scientific controversy. Lakartidningen 2011, 108:1771.
83. Gunzer M., Grabbe S. Dendritic cells in cancer immunotherapy. Crit. Rev. Immunol. 2001, 21:133.
84. Haberer T., Debus J., Eickhoff H., Jakel O., Schulz-Ertner D., Weber U. The Heidelberg Ion Therapy Center. Radiother. Oncol. 2004, 73(Suppl. 2):S186.
85. Han G., You C.C., Kim B.J., Turingan R.S., Forbes N.S., Martin C.T., Rotello V.M. Light regulated release of DNA and its delivery to nuclei by means of photolabile gold nanoparticles. Angew. Chem. Int. Ed. 2006, 45:3165.
86. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57.
87. Harel A., Forbes D.J. Importin beta: conducting a much larger cellular symphony. Mol. Cell 2004, 16:319.
88. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001, 19:47.
89. Hilleman M.R. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 2003, 21:4626.
90. Hirschowitz E.A., Yannelli J.R. Immunotherapy for lung cancer. Proc. Am. Thorac. Soc. 2009, 6:224.
91. Hirschowitz E.A., Hiestand D.M., Yannelli J.R. Vaccines for lung cancer. J. Thorac. Oncol. 2006, 1:93.
92. Hislop A.D., Taylor G.S., Sauce D., Rickinson A.B. Cellular responses to viral infection in human: lessons from Epstein-Barr virs. Annu. Rev. Immunol. 2007, 25:587.
93. Hofbauer G.F., Baur T., Bonnet M.C., Tartour E., Burg G., Berinstein N.L., Dummer R. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 2008, 18:104.
94. Hokey D.A., Larregina A.T., Erdos G., Watkins S.C., Falo L.D. Tumor cell loaded type-1 polarized dendritic cells induce Th1-mediated tumor immunity. Cancer Res. 2005, 65:10059.
95. Holliday R. DNA methylation and epigenetic inheritance. Philos. Trans. R. Soc. Lond. 1990, 326:329.
96. Hong R., Han G., Fernández J.M., Kim B.J., Forbes N.S., Rotello V.M. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc. 2006, 128:1078.
97. Hunter A.M., LaCasse E.C., Korneluk R.G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007, 129:1543.
98. Igarashi E. Factors affecting toxicity and efficacy of polymeric nanomedicines. Toxicol. Appl. Pharmacol. 2008, 229:121.
99. Isobe T., Herbst R.S., Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin. Oncol. 2005, 32:315.
100. Itoh Y., Suzuki T., Miyata N. Isoform-selective histone deacetylase inhibitors. Curr. Pharm. Des. 2008, 14:529.
101. Jakel O., Karger C.P., Debus J. The future of heavy ion radiotherapy. Med. Phys. 2008, 35:5653.
102. Janeway C.A., Travers P., Walport M., Shlomchik M. Immunobiology 5: The Immune System in Health and Disease 2001, Garland Pub., New York. 5th ed.
103. Jinushi M., Tahara H. Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 2009, 100:1389.
104. Joshi B., Wang X., Banerjee S., Tian H., Matzavinos A., Chaplain M.A.J. On immunotherapiesandcancervaccinationprotocols: a mathematical modeling approach. J. Theor. Biol. 2009, 259:820.
105. Kasibhatla1 S., Tseng B. Why target apoptosis in cancer treatment?. Mol. Cancer Ther. 2003, 2:573.
106. Kassis A.I., Adelstein S.J. Radiobiologic principles in radionuclide therapy. J. Nucl. Med. 2005, 46(Suppl. 1):4S.
107. Kennedy R., Celis E. T helper lymphocytes rescue CTL from activation-induced cell death. J. Immunol. 2006, 177:2862.
108. Kennedy R., Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 2008, 222:129.
109. Kersh G.J., Allen P.M. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J. Exp. Med. 1996, 184:1259.
110. Knudson A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 2001, 1(2):157.
111. Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., Yamochi T., Urano T., Furukawa K., Kwabi-Addo B., Gold D.L., Sekido Y., Huang T.H., Issa J.P. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet. 2008, 40:741.
112. Krieg A.M. Toll-free vaccines?. Nat. Biotechnol. 2007, 25:303.
113. Krieg A.M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008, 27:161.
114. Kristensen L.S., Nielsen H.M., Hansen L.L. Epigenetics and cancer treatment. Eur. J. Pharmacol. 2009, 625:131.
115. Lee S.H., et al. Amine-functionalized gold nanoparticles as noncytotoxic and efficient intracellular siRNA delivery carriers. Int. J. Pharm. 2008, 364:94.
116. Lehner P.J., Cresswell P. Processing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol. 1996, 8:59.
117. Levis A.G., Minicucci N., Ricci P., Gennaro V., Garbisa S. Mobile phones and head tumours: it is time to read and highlight data in a proper way. Epidemiol. Prev. 2011, 35:188.
118. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24:99.
119. Liu H., Guo S., Roll R., Li J., Diao Z., Shao N., Riley M.R., Cole A.M., Robinson J.P., Snead N.M., Shen G., Guo P. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol. Ther. 2007, 65:697.
120. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., Zhang Q., Lonning S., Teicher B.A., Lee C. Tumor evasion of the immune system by converting CD4+. J. Immunol. 2007, 178:2883.
121. Lu L., Kanwar J., Schmitt S., Cui Q.C., Zhang C., Zhao C., Dou Q.P. Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant 'thunder god vine'. Anticancer Res. 2011, 31:1.
122. Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8A resolution. Nature 1997, 389:251.
123. Mach N., Gillessen S., Wilson S.B., Sheehan C., Mihm M., Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or flt3-ligand. Cancer Res. 2000, 60:3239.
124. Mai A., Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41:199.
125. Mailliard R.B., Wankowicz-Kalinska A., Cai Q., et al. A-type-1 polarized dendritic cells, a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004, 64:5937.
126. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30:592.
127. Marusawa H., Matsuzawa S., Welsh K., Zou H., Armstrong R., Tamm I., Reed J.C. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003, 22:2729.
128. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301.
129. McKee A.S., Munks M.W., Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007, 27:687.
130. Melero I., Murillo O., Dubrot J., Hervas-Stubbs S., Perez-Gracia J.L. Multilayered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol. Sci. 2008, 29:383.
131. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6:924.
132. Meslin F., Hamaï A., Mlecnik B., Rosselli F., Richon C., Jalil A., Wemhoff G., Thiery J., Galon J., Chouaib S. hSMG-1 is a granzyme B-associated stress-responsive protein kinase. J. Mol. Med. (Berl.) 2011, 89:411.
133. Morgenroth A., Vogg A.T., Mottaghy F.M., Schmaljohann J. Targeted endoradiotherapy using nucleotides. Methods 2011, 55:203.
134. Mulherkar R. Gene therapy for cancer. Curr. Sci. 2001, 81(5):555.
135. Nakahara T., Takeuchi M., Kinoyama I., Minematsu T., Shirasuna K., Matsuhisa A., Kita A., Tominaga F., Yamanaka K., Kudoh M., Sasamata M. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormonerefractory prostate tumor xenografts. Cancer Res. 2007, 67:8014.
136. Nakayama Y., Sakamoto H., Satoh K., Yamamoto T. Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system. Cancer Lett. 2000, 1611:63.
137. Nias A.H.W. An Introduction to Radiobiology 1998, Wiley, Chichester. 2nd ed.
138. Ning Y.M., He K., Dagher R., Sridhara R., Farrell A.T., Justice R., Pazdur R. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park) 2007, 21:1503.
139. Novina C.D., Chabner B.A. RNA-directed therapy: the next step in the miRNA revolution. Oncologist 2008, 131:1.
140. Oehme I., Deubzer H.E., Wegener D., Pickert D., Linke J.P., Hero B., Kopp-Schneider A., Westermann F., Ulrich S.M., von Deimling A., Fischer M., Witt O. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin. Cancer Res. 2009, 15:91.
141. Ogawara K., Un K., Minato K., Tanaka K., Higaki K., Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int. J. Pharm. 2008, 359:234.
142. Old L.J. Cancer is a somatic cell pregnancy. Cancer Immunol. 2007, 7:19.
143. O'Reilly K.M., Mclaughlin A.M., Beckett W.S., Sime P.J. Asbestos-related lung disease. Am. Fam. Physician 2007, 75:683.
144. Oriuchi N., Higuchi T., Hanaoka H., Iida Y., Endo K. Current status of cancer therapy with radiolabeled monoclonal antibody. Ann. Nucl. Med. 2005, 19:355.
145. Ostrand-Rosenberg S. CD4+ T lymphocytes: a critical component of antitumor immunity. Cancer Invest. 2005, 23:413.
146. Pagano J.S., Blaser M., Buendia M.A., et al. Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol. 2004, 14(6):453.
147. Palomba M.L., Roberts W.K., Dao T., et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin. Cancer Res. 2005, 11:370.
148. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 2003, 2t:807.
149. Parkin D.M. The global health burden of infecion-associated cancers in the year 2002. Int. J. Cancer 2006, 118:3030.
150. Parmiani G., Lotze M. Tumor immunology: molecularly defined antigens and clinical applications. Tumor Immunology and Immunotherapy Series 2002, vol.1. Taylor & Francis, London.
151. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 2005, 11:S63.
152. Pennati M., Colella G., Folini M., Citti L., Daidone M.G., Zaffaroni N. Ribozymemediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. J. Clin. Invest. 2002, 1092:285.
153. Pennati M., Binda M., Colella G., Folini M., Citti L., Villa R., Daidone M.G., Zaffaroni N. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J. Invest. Dermatol. 2003, 1204:648.
154. Pennati M., Binda M., De Cesare M., Pratesi G., Folini M., Citti L., Daidone M.G., Zunino F., Zaffaroni N. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004, 257:1129.
155. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007, 286:1133.
156. Pennati M., Folini M., Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin. Ther. Targets 2008, 124:463.
157. Perz J.F., Armstrong G.L., Farrington L.A., Hutin Y.J., Bell B.P. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J. Hepatol. 2006, 45:529.
158. Peter S., Beglinger C. Helicobacter pylori and gastric cancer: the causal relationship. Digestion 2007, 75:25.
159. Podsiadlo P., Sinani V.A., Bahng J.H., Kam N.W., Lee J., Kotov N.A. Gold nanoparticles enhance the antileukemia action of a 6-mercaptopurine chemotherapeutic agent. Langmuir 2007, 24:568.
160. Polizzi M.A., Stasko N.A., Schoenfisch M.H. Water-soluble nitric oxide-releasing gold nanoparticles. Langmuir 2007, 23:4938.
161. Poon I.K., Jans D.A. Regulation of nuclear transport: central role in development and transformation?. Traffic 2005, 6:173.
162. Puerta-Fernandez E., Romero-Lopez C., Barroso-delJesus A., Berzal-Herranz A. Ribozymes: recent advances in the development of RNA tools. FEMS Microbiol. Rev. 2003, 271:75.
163. Qiu L., Jing N., Jin Y. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. Int. J. Pharm. 2008, 361:56.
164. Raez L.E., Fein S., Podack E.R. Lung cancer immunotherapy. Clin. Med. Res. 2005, 3:221.
165. Raza S.A., Clifford G.M., Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br. J. Cancer 2007, 96:1127.
166. Ribas A., Butterfield L.H., Glaspy J.A., Economou J.S. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 2003, 21:2415.
167. Richardson P.G., Anderson K.C. Bortezomib: a novel therapy approved for multiple myeloma. Clin. Adv. Hematol. Oncol. 2003, 1:596.
168. SEER Cancer Statistics Review 2007, 1975. National Cancer Institute, Bethesda, MD. L. Ries, D. Melbert, M. Krapcho, A. Mariotto, B. Miller, E. Feuer, L. Clegg, M. Horner, N. Howlader, M. Eisner, M. Reichman, B. Edwards (Eds.).
169. Robinson H.L., Torres C.A. DNA vaccines. Semin. Immunol. 1997, 9:271.
170. Ryan B.M., O'Donovan N., Duffy M.J. Survivin: a new target for anti-cancer therapy. Cancer Treat. Rev. 2009, 35:553.
171. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005, 6:345.
172. Sandler A.B., Johnson D.H., Herbst R.S. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res. 2004, 10:4258s.
173. Sansonetti P.J. The innate signaling of dangers and the dangers of innate signaling. Nat. Immunol. 2006, 7:1237.
174. Schabowsky R.H., Madireddi S., Sharma R., Yolcu E.S., Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr. Opin. Investig. Drugs 2007, 8:1002.
175. Schabowsky R.H., Sharma R.K., Madireddi S., Srivastava A., Yolcu E.S., Shirwan H. ProtEx™ technology for the generation of novel therapeutic cancer vaccines. Exp. Mol. Pathol. 2009, 86:198.
176. Schulze-Bergkamen H., Krammer P.H. Apoptosis in cancer - implications for therapy. Semin. Oncol. 2004, 31:90.
177. Schwartz R.H. T cell anergy. Sci. Am. 1993, 269(62-63):66.
178. Schwartzentruber D.J., Lawson D.H., Richards J.M., Conry R.M., Miller D.M., Treisman J., Gailani F., Riley L., Conlon K., Pockaj B., Kendra K.L., White R.L., Gonzalez R., Kuzel T.M., Curti B., Leming P.D., Whitman E.D., Balkissoon J., Reintgen D.S., Kaufman H., Marincola F.M., Merino M.J., Rosenberg S.A., Choyke P., Vena D., Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011, 364:2119.
179. Seitz H.K., Pöschl G., Simanowski U.A. Alcohol and cancer. Recent Dev. Alcohol. 1998, 14:67.
180. Shang D., Liu Y., Liu Q., Zhang F., Feng L., Lv W., Tian Y. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett. 2009, 278:82.
181. Sharkey R.M., Goldenberg D.M. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J. Clin. 2006, 56:226.
182. Sharkey R.M., Goldenberg D.M. Use of antibodies and immunoconjugates for the therapy of more accessible cancers. Adv. Drug Deliv. Rev. 2008, 60:1407.
183. Singh M., O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 1999, 17:1075.
184. Singh N.P., Yolcu E.S., Taylor D.D., Gercel-Taylor C., Metzinger D.S., Dreisbach S.K., Shirwan H. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 2003, 63:4067.
185. Singh R.P., Tyagi A., Sharma G., Mohan S., Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin. Cancer Res. 2008, 141:300.
186. Skirtach A.G., Javier A.M., Kreft O., Kohler K., Alberola A.P., Mohwald H., Parak W.J., Sukhorukov G.B. Laser-induced release of encapsulated materials inside living cells. Angew. Chem. Int. Ed. 2006, 45:4612.
187. So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., Sugio K., Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005, 65:5945.
188. Song H., Xin X.Y., Xiao F., Wang D.T., Yue Q.H., Han X. Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 1361:83.
189. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., Krieg A.M., Cerottini J.C., Romero P. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 2005, 115:739.
190. Steele N., Finn P., Brown R., Plumb J.A. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 2009, 100:758.
191. Sugimura T. Cancer prevention: past, present, future. Mutat. Res. 1998, 402:7.
192. Swerdlow A.J., Feychting M., Green A.C., Leeka Kheifets L.K., Savitz D.A. International Commission for Non-Ionizing Radiation Protection Standing Committee on Epidemiology. Mobile phones, brain tumors, and the interphone study: where are we now?. Environ. Health Perspect. 2011, 119:1534.
193. Takahashi Y., Harashima N., Kajigaya S., et al. Regression of human kidney cancer following allogeneic stem cell transplantation is associated with reconition of an HERV-E antigen by T cells. J. Clin. Invest. 2008, 118:1099.
194. Tao G., Hu J., Zou H., Lin Q., Liu F., Wu Y., Sun Q. Therapeutic antitumor response to cervical cancer in mice immunized with U14 vaccines transfected with costimulatory B7 gene. Chin. Med. J. (Engl.) 2001, 114:623.
195. Tasciotti E., Zoppe M., Giacca M. Transcellular transfer of active HSV-1 thymidine kinase mediated by an 11-amino-acid peptide from HIV-1 Tat. Cancer Gene Ther. 2003, 10:64.
196. Thompson S.J., Loftus L.T., Ashley M.D., Meller R. Ubiquitin-proteasome system as a modulator of cell fate. Curr. Opin. Pharmacol. 2008, 8:90.
197. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedmann A., Hawe L.A., Leander K.R., Martinez D., Perry H.C., Shiver J.W., Mongomery D.L., Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745.
198. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., Gejyo F., Okumura K., Yagita H., Smyth M.J. Eradication of established tumors in mice by a combination antibody-based therapy. Nat. Med. 2006, 12:693.
199. Van Parijs L., Peterson D.A., Abbas A.K. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 1998, 8:265.
200. Venook A.P., Papandreou C., Furuse J., de Guevara L.L. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010, 15(Suppl. 4):5.
201. Vlahopoulos S.A., Logotheti S., Mikas D., Giarika A., Gorgoulis V., Zoumpourlis V. The role of ATF-2 in oncogenesis. Bioessays 2008, 30:314.
202. Vogel V.G., Costantino J.P., Wickerham D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 29523:2727.
203. Wagstaff K.M., Jans D.A. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 2006, 13:1371.
204. Wagstaff K.M., Jans D.A. Nuclear drug delivery to target tumour cells. Eur. J. Pharmacol. 2009, 625:174.
205. Waller E.C., McKinney N., Hicks R., Carmichael A.J., Sissons J.G., Wills M.R. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 2007, 110:4360.
206. Wang R., Doolan D.L., Le T.P. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476.
207. Wangler C., Buchmann I., Eisenhut M., Haberkorn U., Mier W. Radiolabeled peptides and proteins in cancer therapy. Protein Pept. Lett. 2007, 14:273.
208. Weber J., Boswell W., Smith J., Hersh E., Snively J., Diaz M., Miles S., Liu X., Obrocea M., Qiu Z., Bot A. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J. Immunother. 2008, 31:215.
209. Wei H., Wang H., Lu B., Li B., Hou S., Qian W., Fan K., Dai J., Zhao J., Guo Y. Cancer immunotherapy using in vitro genetically modified targeted dendritic cells. Cancer Res. 2008, 68:3854.
210. Weide B., Garbe C., Rammensee H.G., Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol. Lett. 2008, 115:33.
211. Weinberg F., Chandel N.S. Mitochondrial metabolism and cancer. Hypoxia and consequences. Ann. N. Y. Acad. Sci. 2009, 1177:66.
212. Weiner D.B., Kennedy R.C. Genetic vaccines. N. Engl. J. Med. 1999, 341:277.
213. Weir H.K., Thun M.J., Hankey B.F., Ries L.A., Howe H.L., Wingo P.A., Jemal A., Ward E., Anderson R.N., Edwards B.K. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003, 95:1276. ([see comment]).
214. Weiss J.F., Landauer M.R. History and development of radiation-protective agents. Int. J. Radiat. Biol. 2009, 85:539.
215. WHO Hepatitis B. Factsheet No 204 2008, World Health Organization, Geneva, Switzerland.
216. WHO Hepatitis C. Factsheet No 164 2011, World Health Organization, Geneva, Switzerland.
217. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science 1990, 247:1465.
218. Xu Z.P., et al. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem. Eng. Sci. 2006, 61:1027.
219. Yaghini E., Yaghini E., Seifalian A.M., MacRobert A.J. Quantum dots and their potential biomedical applications in photosensitization for photodynamic therapy. Nanomedicine 2009, 4:353.
220. Yang L., Yang H., Rideout K., et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol. 2008, 26:326.
221. Yu P., Fu Y.X. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev. 2008, 19:285.
222. Zhang T., Fields J.Z., Ehrlich S.M., Boman B.M. The chemopreventive agent sulindac attenuates expression of the antiapoptotic protein survivin in colorectal carcinoma cells. J. Pharmacol. Exp. Ther. 2004, 3082:434.
223. Zhang M., Berndt B.E., Chen J.J., Kao J.Y. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy. J. Immunol. 2008, 181:3690.
224. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59.
225. Zoller F., Eisenhut M., Haberkorn U., Mier W. Endoradiotherapy in cancer treatment - basic concepts and future trends. Eur. J. Pharmacol. 2009, 625:55.
226. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263.
227. zur Hausen H. Viruses in human cancers. Science 1991, 254:1167.